November 4th, 2026November 2026 preview: 4 FDA decisions to watch in pediatric careFind out the 4 FDA decisions to watch in November 2026 for pediatric care.Read more
October 20th, 2026Tezepelumab sustains EoE remission through 52 weeks Tezepelumab produced histologic remission in up to 68.9% of patients aged 12+ with EoE vs 3.5% with placebo at week 24, sustained to week 52.Read more
November 20th, 2026FDA approves once-weekly somapacitan for children with Turner syndromeThe FDA approved once-weekly somapacitan-beco for growth failure in Turner syndrome in children aged 2.5+ years, based on phase 3 REAL8 data.Read more
November 19th, 2026Tofacitinib curbs interferon signaling in Down syndrome phase 2 trialIn a phase 2 trial, tofacitinib met its safety end point and lowered interferon and cytokine scores in adolescents and adults with Down syndrome.Read more
November 19th, 2026FDA approves venglustat for neurological symptoms of GD3The FDA approved oral venglustat for neurological symptoms of type 3 Gaucher disease in patients ≥15 kg, based on phase 3 LEAP2MONO data.Read more
November 18th, 2026Zilganersen approval brings new treatment approach for Alexander diseaseLaura Tochen, MD, of Children's National Hospital, discusses how the first disease-modifying therapy for Alexander disease could change care and diagnosis.Read more
November 16th, 2026Tirzepatide cuts BMI 18.5% in adolescents with obesityIn SURMOUNT-ADOLESCENTS, tirzepatide cut BMI 18.5% at 72 weeks vs a 0.5% rise with placebo in adolescents with obesity.Read more
November 16th, 2026Roflumilast cream 0.05% eases itch, improves QOL in infants with ADCaregivers reported itch, symptom, and QOL gains with roflumilast cream 0.05% in infants with AD; an FDA decision is due February 2027.Read more